Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $100 from $104 and keeps an Underweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet participates in a conference call with JPMorgan
- Zimmer Biomet price target raised to $89 from $86 at UBS
- Zimmer Biomet price target raised to $98 from $94 at Citi
- Zimmer Biomet Earnings Call Balances Growth and Risk
- Morning Movers: Fiserv and Spotify jump following fourth quarter results